Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells

Abstract excerpt

Emerging evidence has shown that the therapy-induced senescent growth arrest in cancer cells is of durable nature whereby a subset of cells can reinstate proliferative capacity. Promising new drugs named senolytics selectively target senescent cells and commit them into apoptosis. Accordingly, senolytics have been proposed as adjuvant cancer treatment to cull senescent tumor cells, and thus, screening for agents...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Nanoplatforms for cancer theranostics
• Share to Neutrophil, Myeloperoxidase and Oxidative Mechanisms
• Share to Telomeres, Telomerase, and Senescence